Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

2016 ASH Annual Meeting & Exposition

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).

Related Videos


Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residua...


Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as ...


Syed A. Abutalib, MD, and Alex F. Herrera, MD, on Double-Hit and Double-Expressor Lymphomas: A Retrospective Analysis

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest al...


Smita Bhatia, MD, MPH, and Jessica Wu, BA, on CML: A Report From the Bone Marrow Transplant Survivor Study

Smita Bhatia, MD, MPH, and Jessica Wu, BA, both of the University of Alabama at Birmingham, discuss long-term morbidity and mortality experienced by chronic myeloid l...

Hematologic Malignancies
Symptom Management

Brenda M. Sandmaier, MD, and Sagar Lonial, MD, on Preventing GVHD: Clinical Trial Results

Brenda M. Sandmaier, MD, of Fred Hutchinson Cancer Research Center, and Sagar Lonial, MD, of Emory University, discuss study findings on sirolimus combined with mycop...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.